Ltd. Kck Sells 3,720 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

Posted by Brian Wu on Oct 22nd, 2024

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 3,720 shares of the stock in a transaction on Monday, October 21st. The stock was sold at an average price of $6.10, for a total value of $22,692.00. Following the completion of the sale, the insider now owns 5,499,065 shares in the company, valued at approximately $33,544,296.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The stock was sold at an average price of $6.29, for a total value of $30,682.62.
On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The shares were sold at an average price of $6.10, for a total value of $19,050.30.
On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.
On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Stock Down 3.2 %

NPCE stock traded down $0.20 during trading on Tuesday, reaching $6.00. 5,141 shares of the company traded hands, compared to its average volume of 95,523. NeuroPace, Inc. has a 12 month low of $5.73 and a 12 month high of $18.15. The business has a 50 day simple moving average of $7.04 and a 200 day simple moving average of $8.31. The company has a market capitalization of $172.61 million, a price-to-earnings ratio of -5.04 and a beta of 1.78. The company has a debt-to-equity ratio of 5.97, a quick ratio of 5.47 and a current ratio of 6.37.

NeuroPace (NASDAQ:NPCE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. The company had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.36) earnings per share. On average, equities research analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th. Morgan Stanley cut their price target on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Wells Fargo & Company dropped their price objective on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

View Our Latest Stock Report on NeuroPace

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently added to or reduced their stakes in NPCE. Millennium Management LLC boosted its holdings in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after acquiring an additional 80,324 shares in the last quarter. Vanguard Group Inc. boosted its holdings in NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after acquiring an additional 75,512 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in NeuroPace in the first quarter worth about $621,000. Bank of New York Mellon Corp acquired a new stake in NeuroPace in the second quarter worth about $257,000. Finally, Rhumbline Advisers acquired a new stake in NeuroPace in the second quarter worth about $111,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About NeuroPace

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.